No­vo Nordisk plans to ac­quire Ger­man biotech Car­dior Phar­ma­ceu­ti­cals, a Phase 2 RNA start­up, for up to $1.1 bil­lion to boost its pres­ence in car­dio­vas­cu­lar dis­ease, the Dan­ish drug gi­ant said Mon­day morn­ing.
The move comes three weeks af­ter No­vo’s obe­si­ty drug We­govy re­ceived a la­bel ex­pan­sion to in­clude the re­duc­tion of car­dio­vas­cu­lar…